PROKIDNEY CORP. Annual Report: Your Investor's Guide

Discover PROKIDNEY CORP.'s performance for the fiscal year ended December 31, 2025. This summary offers a clear, jargon-free look at their business, financials, and future prospects, designed specifically for investors.

Business Overview

PROKIDNEY CORP. is a clinical-stage biotechnology company aiming to revolutionize chronic kidney disease (CKD) treatment. They primarily focus on developing Renal Autologous Cell Therapy (REACT®), a novel, proprietary cell-based therapy. REACT® is designed to slow or halt CKD progression and potentially restore kidney function. This year, the company focused its main efforts on advancing REACT®, its lead candidate, through pivotal clinical trials.

Financial Performance

For fiscal year 2025, PROKIDNEY CORP. reported no significant revenue, as it remains in clinical development without commercialized products. The company incurred a net loss of approximately $155 million, primarily due to substantial investments in research and development (R&D) and general administrative expenses. R&D expenses alone totaled $128 million, reflecting high costs for large-scale clinical trials, manufacturing development, and regulatory activities. Earnings Per Share (EPS) reached -$1.85 for the year.

Operating expenses, including R&D and administrative costs, increased 25% year-over-year. This contributed to a higher net loss compared to the prior fiscal year. As a pre-revenue company, PROKIDNEY CORP. focuses its growth metrics on clinical and operational milestones rather than traditional revenue or profit growth.

Risk Factors

Investors face several significant risks that could significantly impact the company's business, financial condition, and operational results:

• Clinical Trial Outcomes: PROKIDNEY CORP.'s success depends on positive results from REACT®'s ongoing Phase 3 pivotal trial. Failure to meet primary or secondary endpoints, or unexpected safety concerns, would severely harm the company's prospects and stock price.
• Regulatory Approval: Even with positive trial data, regulatory bodies (like the FDA) may not approve REACT® for commercial use. The approval process for novel cell-based therapies is complex, lengthy, and may involve unforeseen requirements.
• Funding Risk: The company will require substantial additional capital to complete REACT®'s development and bring it to market. Inability to secure adequate funding could delay development, force the company to curtail operations, or dilute existing shareholders.
• Competition: The CKD treatment market is highly competitive. Other companies may develop more effective, safer, or less expensive therapies, or gain market share faster, limiting REACT®'s commercial potential.
• Intellectual Property: The company's success depends on its ability to protect its proprietary technology and intellectual property rights through patents. Challenges to these rights or unauthorized use could undermine its market position.
• Manufacturing and Supply Chain: Developing and scaling up the manufacturing process for a complex cell-based therapy like REACT® is challenging. Any issues with manufacturing, quality control, or the supply chain could delay clinical trials or commercialization.

Key Insights from Management's Discussion & Analysis (MD&A)

Operational Highlights and Achievements:

• Clinical Progress: Completed enrollment for REACT®'s Phase 3 pivotal trial for patients with moderate-to-severe CKD ahead of schedule in Q3 2025. Initial safety data from the ongoing trial remained consistent with previous phases, demonstrating a favorable profile.
• Manufacturing Scale-Up: Scaled up its proprietary manufacturing process for REACT®, positioning the company for potential commercialization.
• Strategic Hires: Strengthened its executive leadership team with key appointments in clinical development and regulatory affairs, adding critical expertise for late-stage development and market entry.

Challenges and Trends:

• Increased Operating Costs: R&D and administrative expenses rose 25% year-over-year, primarily due to the accelerated Phase 3 trial and manufacturing investments, increasing the cash burn rate.
• Competitive Landscape: The CKD treatment market remains highly competitive. Several large pharmaceutical companies and emerging biotechs are developing new therapies, requiring continuous differentiation of PROKIDNEY CORP.'s approach.

Leadership and Strategy Changes: Effective July 1, 2025, PROKIDNEY CORP. completed its "Domestication," relocating its legal incorporation from the Cayman Islands to Delaware, U.S. This strategic move simplifies the company's corporate structure, enhances regulatory oversight by U.S. authorities, and aims to improve access to U.S. capital markets and boost investor confidence through alignment with U.S. corporate governance standards. The company's core strategy remains focused on REACT®'s rapid and successful development, with increased emphasis on commercialization preparation and exploring strategic partnerships to maximize market penetration.

Financial Health

As of December 31, 2025, PROKIDNEY CORP. reported approximately $210 million in cash and cash equivalents. The company carries minimal long-term debt, primarily from a small amount of convertible notes. Based on current operational plans and projected expenditures, management estimates existing cash resources will fund operations into late 2026. However, the company will require additional capital to complete the Phase 3 trial, pursue regulatory approvals, and prepare for commercial launch. PROKIDNEY CORP. actively explores various financing options, including equity offerings, debt financing, and strategic partnerships, to secure this capital.

Future Outlook

Looking ahead, PROKIDNEY CORP.'s key goals and anticipated milestones include:

• Top-line Data Readout: Expects to release top-line data from REACT®'s Phase 3 pivotal trial in mid-2026.
• Regulatory Submissions: If trial results are positive, prepares and submits a Biologics License Application (BLA) to the FDA and similar international regulatory applications by late 2026 or early 2027.
• Commercial Readiness: Continues building commercial infrastructure, including sales and marketing teams, and establishing distribution channels, anticipating potential market approval.
• Pipeline Expansion: Evaluates opportunities to expand its pipeline with additional cell-based therapies for other kidney-related conditions.

Market Trends and Regulatory Changes Affecting Them: The CKD treatment market sees significant innovation, driven by a growing global patient population and a demand for therapies that modify disease rather than just manage symptoms. Strong regulatory emphasis on novel regenerative medicines could streamline approval pathways for therapies like REACT® if they demonstrate significant clinical benefit. However, the regulatory landscape for cell-based therapies still evolves, introducing uncertainties regarding approval requirements and timelines. Increased global awareness and investment in kidney health also create a favorable environment for new, effective treatments.

Competitive Position

PROKIDNEY CORP. believes its REACT® therapy offers a unique CKD treatment approach by targeting the underlying cause of kidney damage through cellular regeneration, rather than symptom management. This differentiates REACT® from existing treatments that primarily focus on blood pressure control, glucose management, or dialysis. While several companies are developing novel CKD therapies, REACT®'s specific mechanism of action and advanced clinical stage position it as a potential first-in-class treatment for a significant patient population with high unmet medical needs. The company aims to leverage its proprietary technology and clinical lead to establish a strong market position upon potential commercialization.